Moreover, aromatase inhibitors, which have improved survival of metastatic breast cancer,47 and trastuzumab, which is dramatically effective in HER2-positive breast cancer,48 were approved for metastatic breast cancer in 2001. Here, ERBB2 is linked to breast carcinoma.